EXUMA Biotech is a clinical-stage biotech company advancing gene vector delivery to enhance patient access to innovative cell and gene therapies.
EXUMABIOTECHNOLOGYHONGKONGLIMITED目前是深圳市百恩维生物科技有限公司直接控股股东,持股比例为100%,是上海埃秀马生物科技有限公司直接控股股东,持股比例为100%;EXUMABIOTECHNOLOGYHONGKONGLIMITED间接持股深圳市百恩维生物科技有限公司、投资占比达100%;目前EXUMABIOTECHNOLOGYHONGKONGLIMITED是3家企业最终受益人,包括其在投资深圳...
简介:EXUMA Biotechnology是一家为亚洲实体肿瘤市场开发CAR-T解决方案的临床阶段生物技术公司,于2016年4月成立,获得了F1 Oncology, Inc.的资本化和独家技术许可。EXUMA Biotechnology的成立旨在最大限度地发挥F1 Oncology在大中华市场的产品和技术的开发和商业化。
近日,埃秀马生物科技(EXUMA Biotechnology)及其子公司上海普珩生物技术有限公司(Shanghai PerHumTherapeutics)今天发布两款人体首剂实体瘤CAR-T产品用于复发或难治IV期转移性肾细胞癌(mRCC)受试者的中期结果。上述数据在癌症免疫治疗学会(CIMT) 2019年会上公布,继续支持CCT301-38 (AXL)和CCT301-59 (ROR2)这两款CA...
/PRNewswire/ -- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and...
5/22,近日,埃秀马生物科技(EXUMA Biotechnology)及其子公司上海普珩生物技术有限公司(Shanghai PerHum Therapeutics)今天发布两款人体首剂实体瘤CAR-T产品用于复发或难治IV期转移性肾细胞癌(mRCC)受试者的中期...
, Sept. 16, 2022 /PRNewswire/ -- Exuma Biotechnology, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, announced that pre-clinical data from its s...
EXUMA Biotech Corp., a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, today announced that preclinical data for the company's next-generation rapid point-of-care, or "rPO
EXUMA Biotech is a clinical-stage biotechnology company pioneering the discovery and development of novel cell and gene therapies for the treatment of solid and hematological malignancies. The company is leveraging a global R&D footprint to advance product candidates ...